Ownership and insider activity for MiNK Therapeutics, Inc. (INKT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction.
Price
| Price | $11.59 |
| Market Cap | $58M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | WIINBERG ULF | A-Award | 1,279 | $14K |
| 2026-09-01 | Holcomb John Bradley | A-Award | 1,233 | $14K |
| 2026-09-01 | Behner Peter | A-Award | 1,485 | $16K |
| 2026-09-01 | Ryan Barbara | A-Award | 1,622 | $18K |
| 2026-09-01 | Corvese Brian | A-Award | 1,633 | $18K |
| 2026-06-04 | Ryan Barbara | S-Sale | 500 | $6K |
| 2026-06-04 | Ryan Barbara | S-Sale | 1,000 | $13K |
| 2026-06-01 | Holcomb John Bradley | A-Award | 1,091 | $14K |
| 2026-03-02 | Holcomb John Bradley | A-Award | 1,239 | $14K |
| 2026-06-01 | Ryan Barbara | A-Award | 1,434 | $18K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $299036 | $2.7M | $38.9M | $19.6M | $3.4M | $4.6M | $13.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $526000 | $254000 | $23000 | 0 | 0 | 0 | 0 |
| Inventory | $87700 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $918400 | $3.6M | $39.6M | $20.4M | $3.6M | $5.0M | $13.8M |
| Property, Plant & Equipment | $390519 | $458384 | $606595 | $1.1M | $953977 | $732929 | $390869 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.3M | $4.6M | $40.2M | $21.5M | $4.6M | $5.7M | $14.2M |
| Accounts Payable | $2.5M | $3.1M | $3.0M | $5.8M | $3.9M | $2.7M | $3.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $5.2M |
| Total Current Liabilities | $7.4M | $14.2M | $16.5M | $12.7M | $11.4M | $7.0M | $13.0M |
| Long-term Debt | $26.8M | $43.8M | 0 | 0 | 0 | $4.9M | 0 |
| Total Liabilities | $37.6M | $58.4M | $16.5M | $21.9M | $22.6M | $25.3M | $28.5M |
| Retained Earnings | -$36.5M | -$52.7M | -$82.9M | -$110.9M | -$133.4M | -$144.2M | -$156.7M |
| Total Equity | -$36.3M | -$53.9M | $23.8M | -$401303 | -$18.1M | -$19.6M | -$14.2M |
| Total Debt | $26.8M | $43.8M | 0 | 0 | 0 | $4.9M | $5.2M |
| Net Debt | $26.5M | $41.1M | -$38.9M | -$19.6M | -$3.4M | $347572 | -$8.2M |
| Working Capital | -$6.5M | -$10.7M | $23.2M | $7.7M | -$7.8M | -$2.0M | $816525 |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.23 |
Profitability
| Return on Equity | 83.45% |
| Return on Invested Capital | -604.20% |
| Return on Assets | -118.15% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CRVO · EQ · GANX · HOWL · IOBT · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of INKT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks